List of Arog Pharmaceuticals, Inc. patents

List of Arog Pharmaceuticals, Inc. patents

List of BSH Hausgeräte patents

List of LS Cable & System patents

List of Vantage Robotics patents

List of companies in The University of Tokyo Edge Capital's investment portfolio

List of SBIR/STTR awards granted to Advanced Materials and Processes

Patents where

Current Assignee

Name

is

Arog Pharmaceuticals, Inc.

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 11471451 Uses of crenolanib	Patent 11471451 was granted and assigned to Arog Pharmaceuticals, Inc. on October, 2022 by the United States Patent and Trademark Office.	Arog Pharmaceuticals, Inc.	Arog Pharmaceuticals, Inc.		United States Patent and Trademark Office	11471451	October 18, 2022
	‌ US Patent 11602533 Crenolanib combination therapy		Arog Pharmaceuticals, Inc.	Arog Pharmaceuticals, Inc.		United States Patent and Trademark Office	11602533	March 14, 2023
	‌ US Patent 10213423 Crenolanib for treating FLT3 mutated proliferative disorders	Patent 10213423 was granted and assigned to Arog Pharmaceuticals, Inc. on February, 2019 by the United States Patent and Trademark Office.	Arog Pharmaceuticals, Inc.	Arog Pharmaceuticals, Inc.		United States Patent and Trademark Office	10213423	February 26, 2019
	‌ US Patent 11007188 Crenolanib for treating FLT3 mutated proliferative disorders	Patent 11007188 was granted and assigned to Arog Pharmaceuticals, Inc. on May, 2021 by the United States Patent and Trademark Office.	Arog Pharmaceuticals, Inc.	Arog Pharmaceuticals, Inc.		United States Patent and Trademark Office	11007188	May 18, 2021
	‌ US Patent 9801870 Crenolanib for treating FLT3 mutated proliferative disorders	Patent 9801870 was granted and assigned to Arog Pharmaceuticals, Inc. on October, 2017 by the United States Patent and Trademark Office.	Arog Pharmaceuticals, Inc.	Arog Pharmaceuticals, Inc.		United States Patent and Trademark Office	9801870	October 31, 2017
	‌ US Patent 9393240 Crenolanib for treating FLT3 mutated proliferative disorders	Patent 9393240 was granted and assigned to Arog Pharmaceuticals, Inc. on July, 2016 by the United States Patent and Trademark Office.		Arog Pharmaceuticals, Inc.		United States Patent and Trademark Office	9393240	July 19, 2016
	‌ US Patent 9101624 Crenolanib for treating FLT3 mutated proliferative disorders	Patent 9101624 was granted and assigned to Arog Pharmaceuticals, Inc. on August, 2015 by the United States Patent and Trademark Office.		Arog Pharmaceuticals, Inc.		United States Patent and Trademark Office	9101624	August 11, 2015
	‌ US Patent 9801869 Method of inhibiting constitutively active phosphorylated FLT3 kinase	Patent 9801869 was granted and assigned to Arog Pharmaceuticals, Inc. on October, 2017 by the United States Patent and Trademark Office.	Arog Pharmaceuticals, Inc.	Arog Pharmaceuticals, Inc.		United States Patent and Trademark Office	9801869	October 31, 2017
	‌ US Patent 9889127 Method of inhibiting mutant C-KIT	Patent 9889127 was granted and assigned to Arog Pharmaceuticals, Inc. on February, 2018 by the United States Patent and Trademark Office.	Arog Pharmaceuticals, Inc.	Arog Pharmaceuticals, Inc.		United States Patent and Trademark Office	9889127	February 13, 2018
	‌ US Patent 9480683 Method of inhibiting mutant C-kit	Patent 9480683 was granted and assigned to Arog Pharmaceuticals, Inc. on November, 2016 by the United States Patent and Trademark Office.		Arog Pharmaceuticals, Inc.		United States Patent and Trademark Office	9480683	November 1, 2016
	‌ US Patent 10251877 Method of inhibiting mutant C-KIT	Patent 10251877 was granted and assigned to Arog Pharmaceuticals, Inc. on April, 2019 by the United States Patent and Trademark Office.	Arog Pharmaceuticals, Inc.	Arog Pharmaceuticals, Inc.		United States Patent and Trademark Office	10251877	April 9, 2019
	‌ US Patent 11458131 Crenolanib for treating FLT3 mutated proliferative disorders		Arog Pharmaceuticals, Inc.	Arog Pharmaceuticals, Inc.		United States Patent and Trademark Office	11458131	October 4, 2022
	‌ US Patent 11642340 Method of inhibiting mutant C-KIT	Patent 11642340 was granted and assigned to Arog Pharmaceuticals, Inc. on May, 2023 by the United States Patent and Trademark Office.	Arog Pharmaceuticals, Inc.	Arog Pharmaceuticals, Inc.		United States Patent and Trademark Office	11642340	May 9, 2023
	‌ US Patent 10780086 Method of inhibiting constitutively active phosphorylated FLT3 kinase	Patent 10780086 was granted and assigned to Arog Pharmaceuticals, Inc. on September, 2020 by the United States Patent and Trademark Office.	Arog Pharmaceuticals, Inc.	Arog Pharmaceuticals, Inc.		United States Patent and Trademark Office	10780086	September 22, 2020
	‌ US Patent 11524006 Crenolanib for treating TRK kinase associated proliferative disorders	Patent 11524006 was granted and assigned to Arog Pharmaceuticals, Inc. on December, 2022 by the United States Patent and Trademark Office.	Arog Pharmaceuticals, Inc.	Arog Pharmaceuticals, Inc.		United States Patent and Trademark Office	11524006	December 13, 2022
	‌ US Patent 11713310 Crystal forms of crenolanib and methods of use thereof		Arog Pharmaceuticals, Inc.	Arog Pharmaceuticals, Inc.		United States Patent and Trademark Office	11713310	August 1, 2023
	‌ US Patent 11857546 Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment	Patent 11857546 was granted and assigned to Arog Pharmaceuticals, Inc. on January, 2024 by the United States Patent and Trademark Office.	Arog Pharmaceuticals, Inc.	Arog Pharmaceuticals, Inc.		United States Patent and Trademark Office	11857546	January 2, 2024
	‌ US Patent 11969420 Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders	Patent 11969420 was granted and assigned to Arog Pharmaceuticals, Inc. on April, 2024 by the United States Patent and Trademark Office.	Arog Pharmaceuticals, Inc.	Arog Pharmaceuticals, Inc.		United States Patent and Trademark Office	11969420	April 30, 2024

18 results

0 selected

18 results

0 selected